You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. CCN3-derrived peptides to treat liver injury

    SBC: BLR Bio            Topic: 200

    Project Summary Chronic liver disease is becoming a major public health issue with estimates of up to 40% prevalence of non- alcoholic fatty liver disease (NAFLD) and 12% with non-alcoholic steatohepatitis (NASH) in the U.S. Liver disease and cirrhosis was the 12th leading cause of mortality in the U.S. in 2014. Obesity and metabolic syndrome are important causes of fatty liver disease or steatosi ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Cell-Based, Chronic Wound Gene Therapy for Older Adults

    SBC: Stratatech Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): According to the Wound Healing Society, about 15% of older adults in the United States suffer from chronic, hard-to-heal skin wounds. An increase in proteolytic activity is associated with intrinsic cutaneous aging predisposing the elderly to tissue breakdown. Furthermore, chronic wounds inherently exhibit a highly proteolytic environment resulting in abnormal ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  3. Cell-Based, Chronic Wound Gene Therapy for Older Adults

    SBC: Stratatech Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): To date no biological treatment options specifically targeting the proteolytic nature of chronic wounds have been developed and marketed. Chronic skin wounds constitute an important medical problem for the growing age d population. 18% of diabetic patients over the age of 65 suffer from chronic, non-healing foot ulcers, and it is estimated that over 50,000 lo ...

    STTR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  4. Cell permeant peptidomimetics to prevent delayed vasospasm and neurological deficits after subarachnoid hemorrhage

    SBC: VasaMetrix            Topic: 107

    PROJECT SUMMARYSubarachnoid hemorrhage (SAH) due to rupture of an intracranial aneurysm leads to delayed vasospasm resulting in neuroischemia (stroke). The overall morbidity (profound neurologic deficit in 10-20% of survivors) and mortality (50%) are high, and the disease affects a relatively young adult population. Therapeutic options to prevent delayed vasospasm and neuroischemia after SAH are c ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  5. Continuous monitoring of anti-fibrinolytic therapy in cardiovascular surgery

    SBC: Micro Vide, LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): A major cause of morbidity and mortality in cardiovascular surgery is excessive bleeding post- operatively, which is commonly managed by pharmacologically modifying clot degradation (fibrinolysis), through inhibition of plasmin activity (PLact). However, the only FDA approved and most commonly used inhibitor of PLact in cardiovascular surgery, while eff ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  6. Continuous monitoring of anti-fibrinolytic therapy in cardiovascular surgery

    SBC: Micro Vide, LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): A major cause of morbidity and mortality in cardiovascular surgery is excessive bleeding post- operatively, which is commonly managed by pharmacologically modifying clot degradation (fibrinolysis), through inhibition of plasmin activity (PLact). However, the only FDA approved and most commonly used inhibitor of PLact in cardiovascular surgery, while effective i ...

    STTR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  7. Custom-Fit Personal Sound Amplification Smartphone Application

    SBC: ASCENDING HEARING TECHNOLOGIES, LLC            Topic: NIDCD

    PROJECT SUMMARYPersonal sound amplification productsPSAPshave recently become available to the publicPSAPs serve a potentially important role in providing audibility of sounds for adults who have difficulty hearing in some daily living situationsbut may not be candidates for traditionalhigh amplification hearing aidsFewer thanof adults with hearing loss reporting use of hearing aidsciting high cos ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Delivery of chemically modified PNA oligomers

    SBC: NUBAD LLC            Topic: NIAID

    PROJECT SUMMARYRNA is a validated target for drug design, both as therapeutic and as a target. Targeting specific RNA, such as rRNA which are involved in proliferation and survival of bacteria is a promising approach. We are developing fast and low cost methods to screen sequence-specific small molecules for novel anti-ribosomal activities. We will construct sequence-specific chemically modified r ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Dense Medium Plasma Remediation of VOCs in Groundwater

    SBC: Orbital Technologies Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): Groundwater is one of the most important freshwater resources on this planet. However, contaminated groundwater has become an ever-increasing problem in the United State. Among the many types of contaminants, Volatile Organic Chemicals (VOCs) are a major concern and a potential human health threat for those who use groundwater for the supply of drinking water. ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  10. Detecting Early Emerging Drug-Resistant HIV Populations

    SBC: ERAGEN BIOSCIENCES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Treatment of human immunodeficiency virus type 1 (HIV) infection with antiretroviral agents invariably leads to selection and accumulation of drug-resistant mutants that arise due to the intrinsically low fidelity of HIV polymerase. Early detection of these growing variants may be clinically relevant. Before the level of clinical importance can be ascertained, ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government